IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting
02 11월 2023 - 10:17PM
IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical
company developing innovative gamma-delta T cell therapies, today
announced an abstract detailing new, positive data from the Phase 1
investigator-sponsored trial of INB-100 in patients with
hematologic malignancies has been selected for poster presentation
at the 65th American Society of Hematology (ASH) Annual Meeting and
Exposition taking place December 9-12, 2023.
Details for the ASH 2023 presentation are as
follows:
Title: INB-100: A Pilot Study of Donor Derived,
Ex-Vivo Expanded/Activated Gamma-Delta T Cell (EAGD) Infusion
Following Haploidentical Hematopoietic Stem Cell Transplantation
and Post-Transplant Cyclophosphamide
(PTCy)Presenter: Joseph McGuirk, DO, The
University of Kansas Cancer CenterAbstract
#: 4853Session Name:
Cellular Immunotherapies: Early Phase and Investigational
Therapies: Poster IIIDate and Time: Monday,
December 11, 2023, 6:00 PM - 8:00 PM PDT
Ten patients have been treated, completing the
dose-escalation of this Phase 1 trial as of the abstract data
cutoff of July 14, 2023. Updated data on safety and efficacy,
including CRs and durability of response will be presented in
December.
About the INB-100 Phase 1
TrialThe Phase 1 clinical trial (NCT03533816) is a
dose-escalation trial of allogeneic derived, gamma-delta T cells
from matched related donors that have been expanded and activated
ex vivo and administered systemically to patients with hematologic
malignancies following hematopoietic bone marrow transplantation
(HSCT). The single-institution clinical trial is currently being
conducted at The University of Kansas Cancer Center (KUCC). The
primary endpoints of this trial are safety and tolerability, and
secondary endpoints include rates of GvHD, relapse rate and overall
survival.
About IN8bioIN8bio is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of gamma-delta T cell product candidates for
solid and liquid tumors. Gamma-delta T cells are a specialized
population of T cells that possess unique properties, including the
ability to differentiate between healthy and diseased tissue.
IN8bio’s DeltEx platform employs allogeneic, autologous, iPSC and
genetically modified approaches to develop cell therapies, designed
to effectively identify and eradicate tumor cells.
IN8bio has initiated a Phase 2 trial of INB-400
in glioblastoma (GBM) at multiple centers across the United States
and has two ongoing Phase 1 trials in solid and hematological
tumors, including INB-200 for GBM and INB-100 for patients with
hematologic malignancies undergoing transplantation. IN8bio also
has a broad portfolio of preclinical programs focused on addressing
other hematological and solid tumor cancers. For more information
about IN8bio and its programs, please visit www.IN8bio.com.
Company Contact:IN8bio, Inc.Patrick McCall+ 1
646.600.6GDT (6438)info@IN8bio.com
Investors & Media:Argot
PartnersIN8bio@argotpartners.com
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
IN8bio (NASDAQ:INAB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024